by Naïm Ouldali, MD; Corinne Levy, MD; Philippe Minodier, MD; Laurence Morin, MD; Sandra Biscardi, MD; Marie Aurel, MD; François Dubos, PhD; Marie Alliette Dommergues, PhD; Ellia Mezgueldi, MD; Karine Levieux, MD; Fouad Madhi, MD; Laure Hees, MD; Irina Craiu, MD; Chrystèle Gras Le Guen, PhD; Elise Launay, PhD; Ferielle Zenkhri, MD; Mathie Lorrot, PhD; Yves Gillet, PhD; Stéphane Béchet, MSc; Isabelle Hau, MD; Alain Martinot, MD; Emmanuelle Varon, MD; François Angoulvant, PhD; and Robert Cohen, MD
Published in JAMA Pediatrics 04 February 2019. doi:10.1001/jamapediatrics.2018.5273
In several countries, 5 years after 13-valent pneumococcal conjugate vaccine (PCV13) implementation, serotype replacement has been reported for invasive pneumococcal disease, which raises concerns about the long-term outcome of PCV13 implementation. The long-term effect of vaccination on community-acquired pneumonia (CAP) remains unknown. This study aimed to assess the long-term outcome of PCV13 implementation on CAP in children.